More Connections, Better Matches: Inside RESI San Diego’s 1,000+ Investor Meeting Success

By Sougato Das, President and COO, LSN

Sougato-Das

RESI San Diego was a powerhouse gathering of 300+ active early-stage life science investors including VCs, angels, family offices, CVCs, venture philanthropy, and pharma external innovation scouts across 10 distinct categories.

What made this event truly remarkable wasn’t just the sheer number of attendees, but their high level of engagement. Throughout the five-day hybrid conference, innovators and capital providers initiated thousands of high-value conversations, reinforcing why RESI remains a premier venue for early-stage companies seeking Seed, Series A, and Series B financing.

RESI San Diego: Partnering Success by the Numbers
The event saw incredible partnering activity, showcasing both high volume and improved precision:

  • 11,000+ Partnering requests submitted.
  • 1,400+ Accepted meetings.

This jump in efficiency reflects a growing emphasis on targeted outreach and thoughtful meeting selection, helping attendees spend less time chasing cold leads and more time speaking with organizations that closely match their technology and fundraising goals.

Furthermore, the hybrid format delivered maximum flexibility.

The RESI Differentiator: Why Our Matches are Stronger
Other industry conferences often suffer from half-empty investor profiles, making it incredibly difficult for fundraising startups to know whom to target. RESI is built differently.

  • Vetted, Highly-Detailed Profiles: Our dedicated Investor Research Team manually populates and verifies every single investor profile in the system. You get the exact detail you need to determine if an investor is a legitimate fit.
  • No “Undercover” Service Providers: Our team meticulously screens every participant to ensure that anyone registered as an investor is actually a legitimate capital provider ready to invest, not financial service providers in disguise.
  • High Visibility on Site: With investors easily identified by their red registration badges, initiating spontaneous, high-value conversations during in-person days was easier than ever.

Maintain Your Fundraising Momentum
Fundraising is a relationship-driven process. The strongest outcomes rarely come from a single meeting; they are built through multiple touchpoints over time. Participating in sequential RESI conferences allows you to strengthen existing relationships, introduce new data milestones, and refine your pitch.

Super Early Bird registration is now open for our upcoming landmark events:

  • RESI Boston (September 2026): Held during Biotech Week Boston, featuring 2 days of expanded in-person programming and 3 days of virtual partnering. (Save $300 if you register by this Friday, July 17!)
  • RESI JPM 2027 (January 2027): Returning to San Francisco during JPM Healthcare Week, the busiest week in healthcare venture capital. 2 days of live networking at the SF Marriott Marquis, followed by 3 days of global virtual partnering.

Lock in the lowest rates of the season today, secure your Super Early Bird pricing, and keep your fundraising momentum moving forward!

Register for RESI Boston Register for RESI JPM

Registration Now Open for RESI JPM 2027 

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Life Science Nation is excited to announce that registration is now open for RESI JPM 2027, taking place January 11–12 at the San Francisco Marriott Marquis, followed by three days of virtual partnering on January 13, 18, and 19. 

Held alongside the world’s largest gathering of healthcare investors, executives, and innovators during JPM Week, RESI JPM provides early-stage life science companies with a unique opportunity to raise capital, build strategic partnerships, and accelerate business development in one of the industry’s most active networking environments. 

Previous RESI JPM conferences welcomed more than 1,000 attendees, including over 600 active investors, strategic partners, pharmaceutical business development professionals, and industry leaders. The conference combines curated educational programming with one-on-one partnering meetings, creating meaningful opportunities for fundraising companies to connect directly with the investors and partners best aligned with their technologies. 

The expanded format begins with two full days of in-person programming at the San Francisco Marriott Marquis, featuring investor panels, educational workshops, the Innovator’s Pitch Challenge, networking events, poster presentations, and partnering meetings. The conference then continues online with three additional days of virtual partnering, allowing participants to maximize the number of meetings they can schedule while extending networking opportunities beyond the in-person event. 

Whether you are seeking Seed, Series A, or Series B financing, exploring strategic partnerships, licensing opportunities, or looking to expand your visibility within the life science investment community, RESI JPM offers multiple ways to engage. Registration options are available for startups, fundraising executives, service providers, technology hubs, exhibitors, and qualified investors. 

Early Bird registration is now available, offering substantial savings on five-day hybrid registration for startups and fundraising executives. Register early to lock in the lowest available rates. 

Organizations looking to maximize their visibility during JPM Week can also take advantage of sponsorship and exhibition opportunities designed to connect brands with a highly targeted audience of investors, innovators, and industry leaders. 

Register today and save up to $900 with Super Early Bird pricing!

Register Now

Don’t miss your opportunity to be part of one of the life science industry’s premier fundraising and partnering events. 

Accelerate Your Fundraising with Life Science Nation’s BD Assist 

By Sougato Das, President and COO, LSN

Sougato-Das

Raising capital is rarely about finding more investors. It’s about finding the right investors, telling the right story, and consistently building relationships that lead to meaningful opportunities. Additionally and importantly, it is about having a dedicated resource that finds those investors, reaches out to them regularly, and secures meetings with them.

Life Science Nation’s BD Assist program was created to help early-stage life science companies do exactly that by making Life Science Nation into that dedicated resource.

BD Assist is LSN’s premier business development program, providing startups with an experienced team dedicated to advancing their fundraising and partnering efforts throughout the year. Designed for companies seeking investment, licensing opportunities, or strategic collaborations, the program combines targeted investor research, strategic messaging, personalized outreach, and ongoing business development support into one comprehensive solution.

Every engagement begins by refining the company’s investment narrative and marketing materials to ensure they clearly communicate the value of the technology, market opportunity, and growth strategy. From there, Life Science Nation identifies and prioritizes a highly targeted global audience of investors and strategic partners whose interests align with the company’s stage, therapeutic area, and business objectives.

With the strategy in place, LSN launches and manages a personalized outreach campaign on the company’s behalf, tracking every interaction through the client’s CRM platform. Outreach is continuously refined based on engagement, allowing companies to build momentum over time while maintaining visibility with investors and corporate partners actively seeking new opportunities.

Clients also benefit from regular strategy discussions, ongoing campaign optimization, and access to Life Science Nation’s extensive global investor ecosystem. For companies participating in RESI conferences, BD Assist extends that support by managing partnering activities and helping maximize high-value meeting opportunities throughout the event.

Unlike traditional consulting services that provide recommendations, BD Assist becomes an extension of your business development team. LSN handles the day-to-day execution so your leadership can remain focused on advancing the science, growing the business, and preparing for meaningful investor conversations.

Whether you are preparing for your first institutional raise, expanding into new markets, or pursuing strategic partnerships, BD Assist provides the expertise, infrastructure, and execution to help accelerate your fundraising journey.

If your goal is to spend less time searching for investors and more time building relationships with the right ones, BD Assist was built for you.

Ready to activate your global roadshow? Click here to fill out the LSN Labs company assessment report and we’ll be in touch with you soon.

Click Here to Fill Out the LSN Labs Company Assessment Report

KBIC Japan Life Science Showcase Strengthens Cross-Border Partnerships at RESI San Diego

By Momo Yamamoto, Senior Investor Research Analyst, LSN

The KBIC Japan Life Science Showcase brought together Japanese innovators, investors, corporate leaders, and government representatives during RESI San Diego to highlight emerging technologies and strengthen collaboration between Japan and the global life science community. As Japan’s largest biomedical cluster and title sponsor of the RESI Conference, the Kobe Biomedical Innovation Cluster (KBIC) brings together approximately 350 companies, medical institutions, and research organizations advancing healthcare innovation. The showcase featured eight Japanese startups selected for their readiness to engage with international investors and licensing partners, providing a platform to introduce their technologies to a global audience.

Each startup delivered a six-minute company presentation followed by five minutes of live Q&A in front of investor judges, giving attendees the opportunity to explore each company’s science, commercialization strategy, and market potential through direct discussions with the founders. The showcase featured an accomplished panel of judges representing Alumni Ventures, Aquillius Ventures, Bristol Myers Squibb, JLABS (Johnson & Johnson), and Mass Medical Angels. Drawing expertise across venture capital, corporate innovation, and early-stage investing, the judges engaged founders with thoughtful questions and constructive feedback, creating meaningful dialogue throughout the session.

Complementing the startup presentations, representatives from JIC Venture Growth Investments and Japan’s Ministry of Economy, Trade and Industry (METI) shared insights into Japan’s evolving venture capital landscape, government initiatives supporting innovation, and the future outlook for the country’s startup ecosystem. Their presentations provided valuable context for international investors interested in partnering with Japanese life science companies.

More than a series of company presentations, the KBIC Japan Life Science Showcase demonstrated the growing momentum behind cross-border collaboration in life sciences. By connecting Japan’s innovative startup ecosystem with U.S. and international investors, strategic partners, and industry leaders, the session reinforced a shared commitment to accelerating healthcare innovation through global partnerships. Events like these continue to strengthen the bridge between regional ecosystems, creating new opportunities for investment, licensing, and commercialization that benefit both the Japanese and international life science communities.

Hot Investor Mandate: Early-Stage Focused Fund Invests in Seed to Series A Rounds in Digital Health and Healthtech Companies

The firm is an early-stage venture capital firm headquartered in Europe and currently investing from its second fund. The firm focuses on startups with proprietary technology and strong global growth potential across deeptech, future of work, fintech, healthtech, and digital health. The firm typically invests in Seed and Series A rounds, generally leading financings while also participating as a syndicate or co-investor when appropriate. Typical investment sizes range from approximately €700K to €1.5M. While the firm invests internationally, companies with connections to the Southeastern European region are viewed favorably.

The firm focuses on healthtech and digital health companies developing software-driven healthcare solutions. The firm is agnostic across healthcare subsectors and disease areas, provided the technology is primarily software-based and demonstrates meaningful innovation, scalability, and commercial potential.

From a company and management team perspective, the firm does not impose strict requirements but values founders with deep domain expertise, strong technological differentiation, and defensible intellectual property. Companies with ties to the Southeastern European ecosystem are considered a plus.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Private Investment Firm with Asset-Centric Approach Invests in Promising Early-Stage Therapeutics Assets

The firm is a private investment firm utilizing an asset-centric drug development model to advance early-stage biopharmaceutical programs. Rather than making traditional company-level investments, the firm primarily invests directly in individual therapeutic assets through flexible and innovative transaction structures. The firm can commit up to $25M or more per program, typically funding development through Phase II clinical proof-of-concept before pursuing value realization through licensing or acquisition by larger pharmaceutical companies. The firm invests globally and maintains a concentrated portfolio of high-potential therapeutic programs.

The firm focuses exclusively on biopharmaceutical assets, including small molecules, biologics, and advanced therapeutic modalities such as cell and gene therapies. The firm evaluates opportunities from approximately 12 to 18 months prior to IND through Phase I clinical development, with a preference for IND-ready, patent-protected programs addressing significant unmet medical needs and offering meaningful commercial potential. The firm is indication-agnostic and is open to a broad range of therapeutic areas where proof-of-concept can be established through early clinical studies.

From a company and management team perspective, the firm seeks founders with deep scientific and pharmacological expertise who are committed to a highly collaborative development model. The firm typically partners with lean, experienced teams and integrates each asset into a dedicated development structure while allowing founders to remain actively involved in program leadership. As a hands-on strategic partner, the firm provides extensive drug development expertise, operational resources, and industry relationships to efficiently advance programs through key value-inflection milestones.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com

Hot Investor Mandate: Asia-Based VC Firm Invests in Early and Growth-Stage Opportunities in Life Sciences, Open to Cross Border Investment

The firm is a government-backed venture capital firm headquartered in Asia. The firm manages a large growth-stage investment fund while increasingly expanding its focus to earlier-stage innovation with global potential. Typical initial investments are approximately $5M, with the flexibility to deploy substantially larger amounts depending on the opportunity. Although the firm has historically invested primarily in domestic growth-stage companies, it is actively seeking early-stage opportunities globally.

The firm invests across therapeutics, digital therapeutics, medical devices, diagnostics, and digital health. Within therapeutics, the firm is modality-agnostic and evaluates opportunities across all disease areas. The firm generally prefers programs that have entered early clinical development and is less inclined to invest in preclinical-stage assets. Beyond therapeutics, the firm remains open to innovative healthcare technologies with strong commercial and global growth potential. From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition. The firm is open to acting as either a lead investor or co-investor and typically seeks board representation when serving as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com